Central role across GALAXY (alcoholic liver fibrosis), MICROB-PREDICT (cirrhosis biomarkers), LiverScreen (population screening for fibrosis), and SPIOMET4HEALTH (liver fat in PCOS).
REGION SYDDANMARK
Danish regional health authority providing clinical infrastructure, patient registries, and real-world deployment sites for European liver disease, eHealth, and precision medicine research.
Their core work
Region of Southern Denmark is a Danish regional public health authority that manages hospitals, healthcare services, and public health initiatives across southern Denmark. In H2020, they contribute real-world clinical data, patient registries, and regional healthcare infrastructure to European research consortia — particularly in liver disease, eHealth implementation, and population health monitoring. They bridge the gap between clinical research and health system deployment, bringing practical experience in how digital health tools and diagnostic protocols are adopted across hospital networks.
What they specialise in
Coordinated ImpleMentAll on tailored eHealth implementation strategies, contributed to ADLIFE on personalized care platforms, and participated in Clinnova digital health centre of excellence.
Contributed hospital discharge data and registry linkage expertise to EUROlinkCAT, tracking outcomes of children with congenital anomalies across Europe.
Participated as third party in ConcePTION, contributing to pregnancy and lactation pharmacovigilance through outcome measures and predictive models.
Engaged in MICROB-PREDICT on microbiome-based cirrhosis biomarkers and IHMCSA on international microbiome coordination and standards.
Participated in EURIPHI on European-wide innovative procurement of health innovation, including value-based healthcare and cross-border care models.
How they've shifted over time
In their early H2020 period (2016–2018), the region focused on clinical registries, congenital anomaly surveillance, and traditional clinical trials such as the HIPGEN cell therapy study — working primarily as a data provider and clinical site. From 2019 onward, their focus shifted decisively toward digital health systems, personalized care platforms, microbiome-based diagnostics, and health system innovation including value-based procurement. This evolution reflects a regional health authority transforming from passive data contributor to active driver of how digital tools and predictive models get deployed in real hospital settings.
Moving toward integrating microbiome diagnostics and AI-driven clinical decision support into routine regional healthcare, making them a strong partner for projects needing real-world health system deployment sites.
How they like to work
Overwhelmingly a participant (12 of 14 projects), with one coordination role in ImpleMentAll — a major eHealth implementation project. With 267 unique partners across 30 countries, they operate as a well-connected node in large European health consortia rather than leading them. Their value lies in providing clinical infrastructure, patient access, and real-world validation environments, making them a reliable institutional partner rather than a scientific driver.
Extensive European network spanning 267 unique partners across 30 countries, indicating deep integration into the continent's health research ecosystem. Their reach is broad rather than concentrated, reflecting participation in large multi-site clinical and public health consortia.
What sets them apart
Unlike universities or research institutes, Region Syddanmark brings the operational reality of a regional health system — hospitals, patient registries, procurement authority, and deployment infrastructure. This makes them irreplaceable for projects that need to move beyond lab results into real clinical environments. Their rare combination of liver disease clinical expertise and eHealth implementation experience positions them uniquely for projects targeting digitally-enabled chronic disease management.
Highlights from their portfolio
- ImpleMentAllTheir only coordinated project (EUR 1.49M) — led a multi-country effort on tailored eHealth implementation strategies, signaling their strongest institutional commitment.
- GALAXYLargest single funding (EUR 1.19M) in a major liver disease consortium studying gut-liver axis in alcoholic fibrosis, anchoring their liver disease expertise.
- MICROB-PREDICTEUR 887K in an ambitious microbiome-based diagnostic project running until 2026, representing their forward-looking investment in precision hepatology.